Aptinyx: Rises on restarting trial of co's nerve damage treatment
Brief: Aptinyx Announces Recommencement Of Phase 2 Study Of Nyx-2925 In Patients With Painful Diabetic Peripheral Neuropathy
U.S. RESEARCH ROUNDUP-Adverum Biotechnologies, Brookfield Asset Management, Utz Brands
U.S. STOCKS ON THE MOVE-Tesla, AT&T Inc, Helix Energy Solutions
Aptinyx slides after pricing equity offering
Brief: Aptinyx Announces Pricing Of Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE- Nikola, Selecta Biosciences, Calix, Twitter
U.S. STOCKS ON THE MOVE- Snap Inc, Nikola, Astrotech Corp
Aptinyx falls on planned equity raise
U.S. RESEARCH ROUNDUP- Humanigen, Netflix, Sprouts Farmers Market
Brief: Aptinyx Estimates That Its Cash And Cash Equivalents Were About $104 Mln As Of Sept 30
Brief: Aptinyx Announces Proposed Public Offering Of Common Stock
Aptinyx: Surges on positive results from PTSD therapy study
Brief: Aptinyx Reports Positive Data From Phase 2 Study of NYX-783 For PTSD
Brief: Aptinyx Recommences Patient Recruitment In Phase 2 Study Of NYX-2925
Brief: Aptinyx Reports Qtrly Loss Per Share $0.27
Brief: Aptinyx To Be Added To Russell 2000 Index
Brief: Aptinyx Completes Enrollment In Phase 2 Exploratory Study Of NYX-783
Brief: Aptinyx Posts Quarterly Loss Per Share $0.34